←
Thomas Pierret 🫁4,621 posts
Thomas Pierret 🫁 avatar

Thomas Pierret 🫁

@TomPrt

#MD #pulmonologist #lungcancer

◷ Joined February 2012▧ 22 Photos and videos
Jordi Remon avatar
⟳ Thomas Pierret 🫁 retweeted
Jordi Remon@JordiRemon·Nov 17

EGFRm NSCLC after osimertinib: How should we weigh PFS when OS is not statistically significant? Recent HAS & FDA decisions on amivantamab and ivonescimab raise a key question: Is delaying progression enough?clinical benefit? Final OS curves from MARIPOSA-2 attached. #LungCancer

Post attachmentPost attachment
Chul Kim avatar
⟳ Thomas Pierret 🫁 retweeted
Chul Kim@chulkimMD·Nov 14

Dr. @laerciolopesMD reviews first-line regimens for TET: chemo + ramucirumab and chemo + IO for thymic carcinoma highlighting (note recent data: ivonescimab + chemo data from #ESMO2026 and the importance of monitoring immune-related adverse events). Great talk! #ITMIG2026

Post attachmentPost attachmentPost attachment
Chul Kim avatar
⟳ Thomas Pierret 🫁 retweeted
Chul Kim@chulkimMD·Nov 14

Dr. @SukiPaddaMD expertly reviews relapsed/refractory TET options: chemotherapy, everolimus (5.8% fatal pneumonitis), antiangiogenic therapy, and IO (high irAE rates) - the latter two mainly for thymic carcinoma. Clinical trials remain essential. #ITMIG2026

Post attachmentPost attachmentPost attachmentPost attachment
Chul Kim avatar
⟳ Thomas Pierret 🫁 retweeted
Chul Kim@chulkimMD·Nov 14

Fantastic talk by Dr. @jennifermarksmd on emerging targets and therapies in TET: bispecifics, MTAP, VEGF inhibition, and ADCs among others. Encouraging progress in systemic therapy! #ITMIG2026

Post attachmentPost attachmentPost attachmentPost attachment
History Girl avatar
⟳ Thomas Pierret 🫁 retweeted
History Girl@HistoryGirlBW·Nov 11

One of the most intense and profound moments in history. 11am on the 11th November 1918 when the guns fell silent. This should be shown in every school.

1:00
Hidehito HORINOUCHI avatar
⟳ Thomas Pierret 🫁 retweeted
Hidehito HORINOUCHI@HHorinouchi·Nov 4

🔥Perioperative ivonescimab ± chemo in resectable NSCLC 🆙 @NatureMedicine 🎯Primary endpoint met 🎯Cohort 2 (ivonescimab + chemo): MPR 70.1% (47/67), pCR 50.7% (34/67), RVT≤5% 97.9% (46/47) 🎯Cohort 1 (monotherapy) MPR 60.0% (6/10), pCR 30.0% (3/10), RVT≤5% 83.3% (5/6) 🎯All patients who underwent surgery achieved R0 🎯Grade ≥3 TRAEs 30.4%; no grade ≥3 hemorrhage or treatment-related death 🎙Dr. Xiaoliang Zhao #LCSM @OncoAlert @Larvol nature.com/articles/s41591-0…

Post attachment
Hidehito HORINOUCHI avatar
⟳ Thomas Pierret 🫁 retweeted
Hidehito HORINOUCHI@HHorinouchi·Nov 1

🔥CRS across CAR-T, T-cell engager & ICI: real-world patient-level comparison (SERIO registry) 🆙 European Journal of Cancer 🎯N=1,765; CRS in 88.7% (CAR-T), 63.3% (TCE), 0.7% (ICI); median onset 2.5 d, <1 d & 21.5 d 🎯Grade ≥3 CRS: 11% (CAR-T), 4% (TCE), 0% (ICI) 🎯Tocilizumab use 90%, 4% & 11% 🎙Dr. Lisa Wein & Dr. Carolin Ertl @OncoAlert @Larvol ejcancer.com/article/S0959-8…

Patrick Forde avatar
⟳ Thomas Pierret 🫁 retweeted
Patrick Forde@FordePatrick·Oct 28

Remarkable results from SBRT +/- immunotherapy for unresected stage I-II NSCLC. No benefit from adding IO & surgery remains standard of care for fit pts w stage I-II, EFS of ~30m w SBRT vs 46-65m for much more advanced disease in trials of neoadj IO #lcsm ascopubs.org/doi/10.1200/JCO…

Clive Peedell avatar
⟳ Thomas Pierret 🫁 retweeted
Clive Peedell@cpeedell·Oct 26

My *practice changing* take home messages from #ESMO26 to NHS lung cancer teams: Immediate change: 1. PERSEE. Bottom line - Chemo still alive for PDL1 >50%. Median OS 50.2m Vs 29.9m. Works just as well for 90-100% group too Fitter, younger should get Chemo even PDL1 100% #ESMO26

Stephen V Liu, MD avatar
⟳ Thomas Pierret 🫁 retweeted
Stephen V Liu, MD@StephenVLiu·Oct 26

#ESMO26 Dr. Jarushka Naidoo @DrJNaidoo with a fantastic discussion on de-escalation trials in oncology. A call out on why de-escalation studies are important and their limitations. And for MOIO in particular - lessons on trial design, non-inferiority, and pragmatism. A must-listen to all involved in trial design. #ESMOAmbassadors

Post attachmentPost attachmentPost attachmentPost attachment